AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 161 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2015. The put-call ratio across all filers is 1.31 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $1,069,000 | -32.4% | 25,623 | -14.4% | 0.00% | -50.0% |
| Q3 2016 | $1,581,000 | +62.8% | 29,935 | +29.2% | 0.00% | +100.0% |
| Q2 2016 | $971,000 | +142.8% | 23,176 | +135.2% | 0.00% | 0.0% |
| Q1 2016 | $400,000 | -51.0% | 9,853 | -21.6% | 0.00% | 0.0% |
| Q4 2015 | $816,000 | -7.4% | 12,567 | +0.6% | 0.00% | 0.0% |
| Q3 2015 | $881,000 | -44.8% | 12,487 | -13.1% | 0.00% | -50.0% |
| Q2 2015 | $1,597,000 | -73.4% | 14,368 | -77.4% | 0.00% | -75.0% |
| Q1 2015 | $6,008,000 | -14.5% | 63,716 | +1.6% | 0.01% | -11.1% |
| Q4 2014 | $7,026,000 | +108.4% | 62,710 | +14.1% | 0.01% | +80.0% |
| Q3 2014 | $3,371,000 | +60.9% | 54,939 | +20.2% | 0.01% | +66.7% |
| Q2 2014 | $2,095,000 | +171.4% | 45,714 | +131.8% | 0.00% | +200.0% |
| Q1 2014 | $772,000 | +70.8% | 19,718 | +4.6% | 0.00% | 0.0% |
| Q4 2013 | $452,000 | -14.9% | 18,858 | -0.6% | 0.00% | 0.0% |
| Q3 2013 | $531,000 | – | 18,978 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |